Adaptyx Biosciences has raised $14 million in seed funding led by Interlagos, bringing total funding to $23 million. Overwater Ventures participated significantly in the round, joined by Starbloom Capital, Stanford University, the Chan Zuckerberg Biohub, Hyperlink Ventures, Cantos Ventures, Humba Ventures, and Seaside Ventures.
The California-based company is developing a wearable patch for continuous monitoring of multiple biomarkers including hormones, small molecules, electrolytes, drugs, and proteins. The technology uses programmable DNA-based molecular switches that bind target molecules and undergo structural changes, enabling continuous tracking.
Among applications in development, the company is exploring hormone optimization for endocrine health and fertility care. Continuous hormone and metabolite profiling could reveal rhythms and imbalances to support precise management. Other applications include heart failure management, drug level monitoring for critical care, and wellness tracking.
“Healthcare suffers from a data deficit,” said Vijit Sabnis, Ph.D., CEO and co-founder of Adaptyx. “Lab tests are only snapshots of health and don’t capture the body’s changing physiology, leaving blind spots that prevent addressing many of today’s health challenges. Adaptyx gives patients and clinicians a continuous view of what’s happening inside the body, transforming previously unseen molecular signals into empowering insights.”
The company operates a Molecular Switch Foundry that integrates automated molecular design, parallelized screening, and AI-driven optimization to accelerate biosensor development. The system aims to expand monitoring capabilities to hundreds of biomolecules.
The funding will accelerate product development, expand the molecular switch pipeline, support clinical trials, and scale the team across engineering, data science, and clinical operations. Adaptyx was founded in 2022 based on research from Stanford University and the Chan Zuckerberg Biohub.
